What You Should Know:
– Genomics plc, a leader in polygenic risk score (PRS) technology, and pharmaceutical giant GSK inks a new collaboration to explore the potential of PRS for optimizing clinical trial design.
– The…
Continue Reading
UK Biobank has today unveiled incredible new data from whole genome sequencing of its half a million participants, a step that is set to drive the discovery of new diagnostics, treatments and cures. The data, uniquely,…
Continue Reading
Amazon Pharmacy is partnering with a slew of pharma companies to offer a new feature that automatically applies manufacturer-sponsored coupons to a patient’s medication order when eligible.The tech giant’s online pharmacy said it’s working…
Continue Reading
Epstein-Barr is among the most common viruses, but no vaccines are available to prevent its infection. Merck is joining the pursuit for a vaccine by striking a deal with Opko Health, paying $50 million…
Continue Reading
MorphoSys, a company whose research has yielded programs placed with big pharmaceutical companies and upstart biotechs, is stopping all preclinical work to focus on cancer, particularly a late-stage drug candidate it acquired in a…
Continue Reading
Multinational pharmaceutical and biotech company Pfizer and AI-powered data company Tempus announced a multi-year strategic alliance to utilize AI and machine learning to inform drug discovery and development in oncology. Pfizer will leverage Tempus’ library…
Continue Reading
What You Should Know:– Tempus, the $10B artificial intelligence and precision medicine company, announced their first multi-omics collaboration with Actuate Therapeutics, in which datasets of different omic groups – genomics, transcriptomics, epigenomics, and others…
Continue Reading
Vir Biotechnology’s Covid-19 research may yield more drugs and perhaps a vaccine, but no longer with the financial support of GSK. The collaboration agreement the two companies struck up in the early days of the pandemic has been amended, leaving Vir to either find another partner or continue its coronavirus research on its own.
The alliance did successfully develop the Covid-19 drug sotrovimab. GSK and Vir will continue to share responsibilities for that drug, which is available under the brand name Xevudy in more than 40 countries. The U.S. is no longer one of them. Last April, the FDA withdrew emergency authorization…
